Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

New England Journal of Medicine

Volumn 356, Issue 22, 2007, Pages 2271-2281

  Hudes, Gary ^a   Carducci, Michael ^b   Tomczak, Piotr ^c   Dutcher, Janice ^d   Figlin, Robert ^e   Kapoor, Anil ^f   Staroslawska, Elzbieta ^g   Sosman, Jeffrey ^h   McDermott, David ⁱ   Bodrogi, István ^j   Kovacevic, Zoran ^k   Lesovoy, Vladimir ^l   Schmidt Wolf, Ingo G H ^m   Barbarash, Olga ⁿ   Gokmen, Erhan ^o   O'Toole, Timothy ^p   Lustgarten, Stephanie ^p   Moore, Laurence ^p   Motzer, Robert J ^q  

^a FOX CHASE CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Klinika Onkologii   (Poland)

^d OUR LADY OF MERCY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g Centrum Onkologii Ziemi Lubelskiej   (Poland)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^j NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^k UNIVERSITY OF DEFENCE   (Serbia)

^l Regional Clinical Center of Urology and Nephrology   (Ukraine)

^m UNIVERSITY OF BONN   (Germany)

ⁿ KEMEROVO STATE MEDICAL UNIVERSITY   (Russian Federation)

^o EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^p PFIZER INC   (United States)

^q MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; TEMSIROLIMUS;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; BIOASSAY; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; HAZARD RATIO; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; INFECTION; KIDNEY CARCINOMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; PAIN; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; WEIGHT REDUCTION;

EID: 34249779568     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa066838     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2006. CA Cancer J Clin 2006;56:106-30.
2. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alpha-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1272-8.
3. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who recieved high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
4. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of highdose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41. [Erratum, J Clin Oncol 2005;23:2877.]
5. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:2972-80.
6. Aass N, De Mulder HM, Mickisch GHJ, et al. Randomized phase II/III trial of interferon alfa-2a with and without 13-cisretinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organization for Research and Treat-ment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 2005;23:4172-8.
7. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
8. Negrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunotherapie. Ann Oncol 2002;13:1460-8.
9. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-41.
10. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253-62.
11. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation factor 4E. Mol Cell Biol 2004;24:200-16.
12. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14.
13. Skotnicki JS, Leone CL, Smith AL, et al. Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779. Clin Cancer Res 2001;7:Suppl:3749S-3750S. abstract.
14. Harding MW. Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin Cancer Res 2003;9:2882-6.
15. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45.
16. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001;8:249-58.
17. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122-7.
18. Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006;66:5549-54.
19. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003;9:4641-52.
20. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-47.
21. Hidalgo M, Buckner JC, Erlichman C, et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006;12:5755-63.
22. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18.
23. Smith II JW, Ko Y, Dutcher J, et al. Phase 1/2 study of intravenous CCI-779 given in combination with interferon-α to patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2004;22:Suppl:14S. abstract.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
25. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;5:549-56.
26. Atkins MB, Sparano J, Fisher RI, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993;11:661-70.
27. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
28. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
29. Bukowski RM, Negrier S, Elson P. Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res 2004;10:6310S-6314S.